Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,502)	$ (2,418)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of intangible assets	696	352
Amortization of right-of-use assets	89	86
Depreciation	625	481
Amortization of deferred financing costs and debt discount	37	0
Provision for (recoveries of) doubtful accounts	13	(54)
Stock-based compensation	368	662
Loss on disposal of property and equipment	17	0
Deferred taxes	0	4
Changes in operating assets and liabilities:
Accounts receivable	448	145
Inventories	(1,198)	132
Prepaid expenses and other assets	85	(65)
Accounts payable	1,148	387
Accrued expenses and other liabilities	175	586
Deferred revenues	(257)	(54)
Operating lease liabilities	(97)	(91)
Net cash (used in) provided by operating activities	(353)	153
Cash flows from investing activities:
Purchase of property and equipment	(679)	(740)
Cash paid in connection with TheraClear asset acquisition	(631)	0
Net cash used in investing activities	(1,310)	(740)
Net decrease in cash, cash equivalents and restricted cash	(1,663)	(587)
Cash, cash equivalents and restricted cash, beginning of period	12,586	18,112
Cash, cash equivalents and restricted cash, end of period	10,923	17,525
Cash and cash equivalents	10,923	10,043
Restricted cash	0	7,482
Supplemental disclosure of cash flow information:
Cash paid for interest	160	30
Supplemental disclosure of non-cash operating, investing and financing activities:
Inventories acquired in connection with TheraClear asset acquisition	71	0
Intangible assets acquired in connection with TheraClear asset acquisition	10,182	0
Contingent consideration issued in connection with TheraClear asset acquisition	9,122	0
Common stock issued in connection with TheraClear asset acquisition	$ 500	$ 0